Salva_Tori
Nuovo Utente
- Registrato
- 12/6/07
- Messaggi
- 10.890
- Punti reazioni
- 284
dovesse uscire qualcosa di più sul COVID-19
basta vedere le salite mostruose
che hanno fatto tutti i titoli relativi ...
Qlgn
- Creatore Discussione coffeman
- Data di inizio
dovesse uscire qualcosa di più sul COVID-19
basta vedere le salite mostruose
che hanno fatto tutti i titoli relativi ...
Abbiamo registrato il profondo paragone col il pizzettaro.
A questo punto potevi scendere e investire in un paio di trancetti, il ruttino successivo sarebbe stata analisi finanziariamente migliore.
Il tempo sarà galantuomo.
A questo punto potevi scendere e investire in un paio di trancetti, il ruttino successivo sarebbe stata analisi finanziariamente migliore.
Il tempo sarà galantuomo.
Salva_Tori
Nuovo Utente
- Registrato
- 12/6/07
- Messaggi
- 10.890
- Punti reazioni
- 284
E' da lunedì 18 che scende ben nove giorni di borsa senza soluzione di continuità
per me vuol dire qualcosa , poi magari sbaglio non voglio influenzare nessuno
per me vuol dire qualcosa , poi magari sbaglio non voglio influenzare nessuno
Salva_Tori
Nuovo Utente
- Registrato
- 12/6/07
- Messaggi
- 10.890
- Punti reazioni
- 284
anche secondo me, proviamo ad insultarla vediamo se reagisce questo supercesso
speriamo che non se la prende a male
Seneca71
Free connections, expand your social circle
- Registrato
- 10/5/07
- Messaggi
- 12.512
- Punti reazioni
- 417
mi sono letto tutto il pippotto uscito oggi...a me non sembra così' messa male...certo ci sono dubbi sulla continuità aziendale ma ho letto anche elementi positivi...certo che per mettere in pratica quello che hanno in mente avranno bisogno di notevoli finanziamenti.
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) showed a performance of -55.66% in past 30-days. Number of shares sold short was 41.34 Million shares which calculate 0.06 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $175 to the stock, which implies a rise of 3128.78% to its current value. Analysts have been projecting $175 as a low price target for the stock while placing it at a high target of $175. It follows that stock’s current price would jump +3128.78% in reaching the projected high whereas dropping to the targeted low would mean a loss of 3128.78% for stock’s current value.
Wtf????
Wall Street analysts have assigned a consensus price target of $175 to the stock, which implies a rise of 3128.78% to its current value. Analysts have been projecting $175 as a low price target for the stock while placing it at a high target of $175. It follows that stock’s current price would jump +3128.78% in reaching the projected high whereas dropping to the targeted low would mean a loss of 3128.78% for stock’s current value.
Wtf????
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 12.309
- Punti reazioni
- 1.290
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) showed a performance of -55.66% in past 30-days. Number of shares sold short was 41.34 Million shares which calculate 0.06 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $175 to the stock, which implies a rise of 3128.78% to its current value. Analysts have been projecting $175 as a low price target for the stock while placing it at a high target of $175. It follows that stock’s current price would jump +3128.78% in reaching the projected high whereas dropping to the targeted low would mean a loss of 3128.78% for stock’s current value.
Wtf????
una ******ta
Salva_Tori
Nuovo Utente
- Registrato
- 12/6/07
- Messaggi
- 10.890
- Punti reazioni
- 284
Sono andato a guardare indietro e finalmente ho chiarito l’episodio:
Seneca71 scrive :
secondo te farà il rimbalzone del gatto morto??
Al momento ricordavo come questa frase fosse stata scritta da te, al che ti ho risposto scherzando:
Salva_Tori
anche il funerale del gatto morto
dico non è che scappa il morto , poi se morto come fa a scappare
a volte si è distratti e/o la memoria ci inganna
in sostanza non intendevo offenderti
grazie del rosso comunque , rosso di sera buon tempo si spera
avrai almeno apprezzato il bollino verde che ti ho dato
Sestante67
Nuovo Utente
- Registrato
- 16/2/15
- Messaggi
- 1.303
- Punti reazioni
- 11
Quando lo hanno fatto e anche prezzo.
Grazie
Sestante67
Nuovo Utente
- Registrato
- 16/2/15
- Messaggi
- 1.303
- Punti reazioni
- 11
Salva_Tori
Nuovo Utente
- Registrato
- 12/6/07
- Messaggi
- 10.890
- Punti reazioni
- 284
Sestante67
Nuovo Utente
- Registrato
- 16/2/15
- Messaggi
- 1.303
- Punti reazioni
- 11
Sestante67
Nuovo Utente
- Registrato
- 16/2/15
- Messaggi
- 1.303
- Punti reazioni
- 11
Comunque uscisse una new, non può sempre calare,,,,.
Sestante67
Nuovo Utente
- Registrato
- 16/2/15
- Messaggi
- 1.303
- Punti reazioni
- 11
Vedo ora +8,,,,,
Cosa c è ,,,,?
Cosa c è ,,,,?
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 12.309
- Punti reazioni
- 1.290
Qualigen Therapeutics Submits Notification to FDA to Commence Distribution of its FastPack(R) COVID-19 Antibody Test :: Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc.
ABOUT US
THERAPEUTICS
DIAGNOSTICS
PATIENTS
INVESTORS
CUSTOMER SUPPORT
Press Releases
Overview
News & Events
Company Info
Stock Data
SEC Filings
Governance
NEWS & EVENTS
Overview
Press Releases
IR Calendar
Email Alerts
Qualigen Therapeutics Submits Notification to FDA to Commence Distribution of its FastPack® COVID-19 Antibody Test
Download as PDFJULY 01, 2020 8:00AM EDT
CARLSBAD, Calif., July 1, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company") announces it has submitted an official notification to the U.S. Food and Drug Administration ("FDA") to commence sales in the U.S. of the Company's FastPack® SARS-CoV-2 IgG test for COVID-19 antibodies. This test has already been submitted to the FDA for Emergency Use Authorization ("EUA"), but the notification enables Qualigen to commence sales even before the FDA considers or formally grants the EUA for the test. Qualigen expects sales and shipments of the new test to begin in mid-July.
The FastPack® COVID-19 antibody test is a chemiluminescent microparticle test intended for the qualitative detection (i.e., yes/no) of SARS-CoV-2 IgG antibodies in blood to identify individuals with an adaptive immune response to the virus that causes COVID-19, indicating recent or prior infection of the disease (which, as a practical matter, is believed to be indicative of immunity against re-infection). Qualigen's FastPack® test uses a specific protein that is also used by major diagnostics companies including Abbott Laboratories, Roche Diagnostics and Bio-Rad Laboratories in their COVID-19 antibody tests. The important advantage of FastPack® over testing in large commercial laboratories, however, is its ability to deliver accurate results far more rapidly, in this case under 10 minutes, in physician offices, clinics and hospitals.
"Of the different options available, we chose to develop a test specific to the IgG antibody because IgG represents the long-term immune response. We believe our test's combination of high speed and high accuracy provides the clinician with more useful and actionable information than other testing approaches," Michael Poirier, the Company's CEO, explained. "We believe that reliable, yet convenient testing at the point-of-care is critical to helping combat this virus and get Americans back to their normal routines."
The new test is designed for use with Qualigen's new FastPack® PRO System point-of-care diagnostic instruments. The FastPack® PRO System is an upgraded version of Qualigen's flagship FastPack® IP rapid immunoassay diagnostic point-of-care system.
Qualigen has been producing high-quality diagnostic testing products for almost 20 years, and has established a strong reputation for delivering highly accurate point-of-care tests that help save people's lives.
About the FastPack® System
The FastPack® System is a rapid and highly accurate immunoassay testing system consisting of the FastPack® Analyzer and the FastPack® test pouch (a single-use, disposable, foil packet that includes the FastPack® reagent chemistry). This "Laboratory in a Pouch" is installed in physician offices, clinics and small hospitals around the world, and quickly detects diseases and medical conditions at the point-of-care. Since the conception of the system, the Company has expanded its assay menu to 10 tests including tests for prostate cancer, thyroid function, metabolic disorders, antibodies against SARS-CoV-2, and research applications. Over the past 20 years, FastPack® has generated more than $100 million in commercial sales. Qualigen's worldwide distributor for FastPack® is Sekisui Diagnostics, LLC, a subsidiary of a multibillion-dollar Japanese chemical and technology company; Sekisui, in turn, works with national distributors including McKesson Corporation and Henry Schein Inc.
Qualigen Therapeutics, Inc.
ABOUT US
THERAPEUTICS
DIAGNOSTICS
PATIENTS
INVESTORS
CUSTOMER SUPPORT
Press Releases
Overview
News & Events
Company Info
Stock Data
SEC Filings
Governance
NEWS & EVENTS
Overview
Press Releases
IR Calendar
Email Alerts
Qualigen Therapeutics Submits Notification to FDA to Commence Distribution of its FastPack® COVID-19 Antibody Test
Download as PDFJULY 01, 2020 8:00AM EDT
CARLSBAD, Calif., July 1, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company") announces it has submitted an official notification to the U.S. Food and Drug Administration ("FDA") to commence sales in the U.S. of the Company's FastPack® SARS-CoV-2 IgG test for COVID-19 antibodies. This test has already been submitted to the FDA for Emergency Use Authorization ("EUA"), but the notification enables Qualigen to commence sales even before the FDA considers or formally grants the EUA for the test. Qualigen expects sales and shipments of the new test to begin in mid-July.
The FastPack® COVID-19 antibody test is a chemiluminescent microparticle test intended for the qualitative detection (i.e., yes/no) of SARS-CoV-2 IgG antibodies in blood to identify individuals with an adaptive immune response to the virus that causes COVID-19, indicating recent or prior infection of the disease (which, as a practical matter, is believed to be indicative of immunity against re-infection). Qualigen's FastPack® test uses a specific protein that is also used by major diagnostics companies including Abbott Laboratories, Roche Diagnostics and Bio-Rad Laboratories in their COVID-19 antibody tests. The important advantage of FastPack® over testing in large commercial laboratories, however, is its ability to deliver accurate results far more rapidly, in this case under 10 minutes, in physician offices, clinics and hospitals.
"Of the different options available, we chose to develop a test specific to the IgG antibody because IgG represents the long-term immune response. We believe our test's combination of high speed and high accuracy provides the clinician with more useful and actionable information than other testing approaches," Michael Poirier, the Company's CEO, explained. "We believe that reliable, yet convenient testing at the point-of-care is critical to helping combat this virus and get Americans back to their normal routines."
The new test is designed for use with Qualigen's new FastPack® PRO System point-of-care diagnostic instruments. The FastPack® PRO System is an upgraded version of Qualigen's flagship FastPack® IP rapid immunoassay diagnostic point-of-care system.
Qualigen has been producing high-quality diagnostic testing products for almost 20 years, and has established a strong reputation for delivering highly accurate point-of-care tests that help save people's lives.
About the FastPack® System
The FastPack® System is a rapid and highly accurate immunoassay testing system consisting of the FastPack® Analyzer and the FastPack® test pouch (a single-use, disposable, foil packet that includes the FastPack® reagent chemistry). This "Laboratory in a Pouch" is installed in physician offices, clinics and small hospitals around the world, and quickly detects diseases and medical conditions at the point-of-care. Since the conception of the system, the Company has expanded its assay menu to 10 tests including tests for prostate cancer, thyroid function, metabolic disorders, antibodies against SARS-CoV-2, and research applications. Over the past 20 years, FastPack® has generated more than $100 million in commercial sales. Qualigen's worldwide distributor for FastPack® is Sekisui Diagnostics, LLC, a subsidiary of a multibillion-dollar Japanese chemical and technology company; Sekisui, in turn, works with national distributors including McKesson Corporation and Henry Schein Inc.
